| Expression pattern: |
UP |
| Associated gene: |
PD-L1 mRNA, soluble PD-L1 (sPD-L1), PD-L1, CD80, CD70, CD155, CD43 |
| Associated microRNA: |
miR1299, miR-142-5p |
| Biological function: |
promotes tumorigenesis (proliferation, migration, invasion, wound healing) and promotes immune evasion by increasing soluble PD-L1, potentially contributing to immunotherapy resistance |
| Molecular mechanism: |
circRNA-miRNA-mRNA axis (proposed/assessed) involving miR1299 and miR-142-5p; upregulates PD-L1 mRNA and increases secretion of soluble PD-L1 (sPD-L1), which may hinder anti-PD-L1 antibody efficacy and T-cell activation |
| Biological pathway or process: |
migration (promotes); invasion (promotes); proliferation (promotes); immune regulation (promotes); other pathway/process (other) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RT-qPCR; Transfection; CCK8; Transwell Assay; Wound Healing Assay; ELISA; Western Blot; In Vivo Animal Model; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
Upregulated plasma hsa_circ_0000190 level was associated with poor response to immunotherapy and may serve as a blood-based biomarker to monitor disease progression and efficacy of immunotherapy. |
| Description: |
In NSCLC, hsa_circ_0000190 (C190) promotes tumorigenic behaviors (proliferation, migration, invasion) and enhances tumor growth in xenografts. It elevates PD-L1 mRNA and increases secretion of soluble PD-L1 (sPD-L1), which may reduce anti-PD-L1 efficacy and T-cell activation, contributing to immune evasion and immunotherapy resistance. |
| Confidence score: |
0.6542 |